Results 51 to 60 of about 1,457,629 (200)
Aims The phase 3 ECHO trial demonstrated superior progression‐free survival (PFS) with acalabrutinib plus bendamustine‐rituximab (BR) versus placebo plus BR in treatment‐naive (TN) mantle cell lymphoma (MCL). This analysis characterizes the pharmacokinetic (PK) profile of acalabrutinib and ACP‐5862 (active metabolite) when administered with BR and ...
Damilola Olabode +7 more
wiley +1 more source
Strategies to overcome resistance to FMS-like tyrosine kinase 3 (FLT3)-targeted therapy in acute myeloid leukemia (AML) are urgently needed.
Weiguo Zhang +14 more
doaj +1 more source
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin +10 more
wiley +1 more source
B cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype. There is scarcity of data regarding treatment and existing therapies induce short lived remissions.
Maria Tariq Siddiqui +3 more
doaj +1 more source
The Origins of Allergy: An Outside‐In, Bioenergetic Hypothesis
ABSTRACT Allergic disease has risen too rapidly for inherited susceptibility to explain it, and the risk variants so far reported lie in the epithelial barrier and in type‐2 immunity. We propose a five‐layer model in which epithelial barrier and bioenergetic dysfunction may precede and promote type‐2 immune deviation rather than arise solely as its ...
Peter K. Smith +9 more
wiley +1 more source
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa +25 more
wiley +1 more source
EGF regulates tyrosine phosphorylation and membrane-translocation of the scaffold protein Tks5 [PDF]
Background: Tks5/FISH is a scaffold protein comprising of five SH3 domains and one PX domain. Tks5 is a substrate of the tyrosine kinase Src and is required for the organization of podosomes/invadopodia implicated in invasion of tumor cells.
Geiszt, Miklós +5 more
core +1 more source
Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
Ana Lorenzo-Vizcaya,1 Serena Fasano,2 David A Isenberg3 1Department of Internal Medicine, Hospital Universitario De Ourense, Ourense, Spain; 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Campania L.
Lorenzo-Vizcaya A, Fasano S, Isenberg DA
doaj
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz +45 more
wiley +1 more source
Summary Younger patients with high‐risk diffuse large B‐cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R‐CHOEP+I) in patients aged 18–60 years with DLBCL and age‐adjusted international prognostic index ≥2.
Evgenii Shumilov +19 more
wiley +1 more source

